

Renewal and Growth

2023 Investors' Meeting

December 6, 2023

Safe Harbor Statement

This presentation contains certain forward-looking statements.

These forward-looking statements may be identified by words such as ‘believes,’ ‘expects,’ ‘anticipates,’ ‘projects,’ ‘intends,’ ‘should,’ ‘seeks,’ ‘estimates,’ ‘future,’ or similar expressions or by discussion of, among other things, strategy, goals, plans, or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

- 1.Pricing and product initiatives of competitors
- 2.Legislative and regulatory developments and economic conditions
- 3.Delay or inability in obtaining regulatory approvals or bringing products to market
- 4.Fluctuations in currency exchange rates and general financial market conditions
- 5.Uncertainties in the discovery, development, or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products
- 6.Increased government pricing pressures
- 7.Interruptions in production
- 8.Loss of or inability to obtain adequate protection for intellectual property rights
- 9.Litigation
- 10.Loss of key executives or other employees
- 11.Adverse publicity and news coverage

OBI Pharma cautions that this foregoing list of factors is not exhaustive. There may also be other risks that management is unable to predict at this time that may cause actual results to differ materially from those in forward-looking statements. **You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. OBI undertakes no obligation to update publicly or revise any forward-looking statements.**

Any statements regarding earnings growth is not a profit forecast and should not be interpreted to mean that OBI’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed published earnings or earnings per share forecasts of OBI Pharma, Inc.


Agenda



01
**Opening
Remarks**



02
**Financial
Overview**



03
Discovery



04
**Clinical
Development**



05
**Closing
Remarks**

01 Opening Remarks

Chief Executive Officer
Heidi Wang, Ph.D.



OBI Pharma: Renewal and Growth



Pipeline



Our People




**Culture &
Corporate
Responsibility**



OBI Pharma – Building the Pipeline of the Future

TARGETS

Globo H, SSEA4, AKR1C3, TROP2, Nectin4, HER2 and other potential targets.







Broad Oncology Pipeline with Renewed Focus on ADC

PRODUCT	TYPE	TARGET	CANCER	DISCOVERY	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3
Adagloxad Simolenin	Vaccine	Globo H	Breast (TNBC)					
OBI-833	Vaccine	Globo H	NSCLC					
OBI-3424	Prodrug	AKR1C3	Multiple Cancers					
OBI-866	Vaccine	SSEA4	Multiple Cancers					
OBI-999	ADC (ThioBridge™ conjugation)	Globo H	Multiple Cancers					
OBI-992	ADC (Cys-conjugation platform)	TROP2	Multiple Cancers					
OBI-902	ADC (GlycOBI™ platform)	TROP2	Multiple Cancers					
OBI-904	ADC (GlycOBI™ platform)	Nectin4	Multiple Cancers					
OBI-905	ADC (GlycOBI™ platform)	HER2	Multiple Cancers					
BsADC	ADC (GlycOBI™ platform)	TROP2, HER2	Multiple Cancers					



ADC: A Novel Targeted Therapy



ADCs – the Paradigm Shifts in Cancer Therapy



More ADCs

entered the clinic than
**immune checkpoint
inhibitors** in
H1 2023¹

\$ 36B

Global ADC market
targeted worth
by 2029²

150+deals

in 2018-2023
40% in preclinical
stage³

+ 400%

growth in total deal
value of ADC from
2017-2022³

¹ World ADC conference 2023.

² GlobalData, Pharma Intelligence Center.

³ GlobalData, Report Code: GDHC5469EI.

• Image by starline on Freepik




Glyc **OBI**™

Two Distinct Platforms– Plug & Play

Cystine-Based ADC Platform

OBI-992




- Differentiated hydrophilic linker
- Optimized DAR4
- Cysteine conjugation

Topoisomerase I inhibitor (TOP1i) payload

Proprietary ADC Platform

OBI-902, OBI-904, OBI-905



TOP1i payload

- Proprietary enzyme technology (EndoSyme **OBI**)
- Site-specific conjugation
- Next generation novel linker
- Homogenous DAR4, DAR8 or DAR-X ADC




Proprietary ADC Platform – *designable*



Potential First-in-Class & Best-in-Class ADCs

OBI Next Generation ADC Technology

EndoSyme **OBI**[™] Glyc **OBI**[™]



A “*designable*” ADC




For any mAbs	Better efficacy
Lower toxicity	Consistent quality

Site-specific Homogeneous ADC



Comprehensive Worldwide Patent Coverage



1. The provided number represents the total cases filed in different jurisdictions, not patent family.
2. Certain patent rights limited to designated jurisdictions, not worldwide.



Experienced Drug Developers

Industry Experience

Director and Above (n=18)

Total
355+ years

Average
19+ years

Education

81%(125/155)
have advanced degrees

43
Ph.D./ MD/ Pharm.D.

82
M.S/ M.A.

Newly Established

- **Biostatistics Group**
- **Development Teams & Champions**
- **Project Management Office**

Our Culture



Developing ESG as OBI's DNA



Environmental



In 2022, energy saved by **12%** vs. 2021.



In 2023, **preliminary greenhouse gas inventory completed.**



Sep 2023
Moved into TBIP, an **environmentally friendly green building**



Developing ESG as OBI's DNA

Social 



The welfare and vacation policies are **much better than required by the Labor Standards Act.**

Certified by the Ministry of Education:



OBI is a sports enterprise.



The average training hours per employee in 2022 was **14.22 hours.**

Social welfare activities



▲ Supports patient groups



▲ Promotes OBI Volunteer Day; employees actively respond.



▲ Organizes regular blood donation events



Developing ESG as OBI's DNA



Governance

Ranked **2nd**
among the national
"Top 5000"
biotechnology
companies



ISO/IEC 27001
Certified for
Information Security
in 2023



A diversified,
professional and
independent board
Average attendance
rate in 2022: **94%**

02 Financial Overview

Head of Finance
Colin Kao



OBI Pharma, Inc. (4174.TWO)

www.obipharma.com

Founded	April 29, 2002
IPO on TPEX	March 23, 2015
Market Cap (Nov. 30, 2023)	~US\$ 613M
Fund Raised at IPO	~US\$ 200M
Fund Raised in 2019	~US\$ 65M
Fund Raised in 2022	~US\$ 102M
Cash on Hand (Nov. 30, 2023)	~US\$ 61M
Employees	155



03 Discovery


Chief Scientific Officer
Ming-Tain Lai, Ph.D.





Antibody-Drug-Conjugates (ADC)

ADC: Novel Target Therapy



The Mechanism of Action of ADC after Entering Bloodstream




1 ADC in blood circulation



2 ADC binds to target antigen



3 ADC-antigen complex internalized into cancer cells



4 Cytotoxic agent is released



5 Cancer cells killed






ADC Format Enables the Flexibility to Develop Novel Pipelines

Antibody



- Tumor specific
- Unaltered target binding affinity



Linker



- Stable in plasma
- Internalized by cell
- Drug release inside the cell

Drug





- High potency payload
- TOP1 inhibitor
- DNA strand breaks

TROP2抗體：2021年12月自博奧信公司(Biosion, Inc.)授權引進



ADC: The Focus of OBI Drug Development




TROP2: Two Platforms



Nectin4 & HER2:



Bispecific ADC:



Unmet needs drive instant uptake of new ADCs

TROP2 (Trodelvy®)



Nectin4 (Padcev®)



HER2 (Enhertu®)






OBI-992













TROP2-Targeting ADC

OBI-992: TROP2-targeting ADC with potent payload















OBI-992 is designed to be the Best-in-Class

OBI-992 has a better in vitro profile than Trodelvy® or Dato-DXd

		OBI-992	Trodelvy®*	Dato-DXd**
Binding affinity		+++ 	++	+
Specificity to tumor antigen		+++ 	+++ 	++
Serum stability		+++ 	+	++
Pharmacokinetics	Exposure	+++ 	+	++
	Clearance	+++ 	+	++
	Half-life	+++ 	+	++
Payload potency		+++ 	+	++
Payload cell permeability		+++ 	NA	++
Payload drug resistance		+ 	+++	+++
Non-specific binding		+ 	+ 	+++

OBI-992 has a better in vivo profile than Trodelvy® or Dato-DXd

		OBI-992	Trodelvy®	Dato-DXd
CDX animal models*	NSCLC	100% 	39%	87%
	Pancreatic	100% 	54%	85%
	Gastric	100% 	NA	96%
PDX animal model*	NSCLC	100% 	NA	80%
	Gastric	100% 	NA	85%
Efficacy in drug resistance models*		100% 	33%	42%
PK/PD models (drug release in tumor)		+++ 	NA	++
Induction of immunogenic cell death		+++ 	+++ 	++
Synergistic effect with anti-PD-1		+++ 	NA	NA
Synergistic effect with PARP inhibitor		+++ 	NA	NA
Therapeutic Index		+++ 	++	+

OBI-992: IND Submitted to FDA





OBI-902

TROP2-Targeting ADC


OBI-905

HER2-Targeting ADC





Proprietary ADC Platform: Glyc **OBI**™







OBI-902 and OBI-905



ADCs have better profiles than competitors

TROP2 ADCs	OBI-902	Dato-DXd
Serum stability	+++ 	+
Off-target toxicity (neutrophil)	+ 	+++
Off-target FcγR mediated toxicity	+ 	+++
In vivo efficacy (TNBC CDX model)*	100 % 	66 %

HER2 ADCs	OBI-905	Enhertu®
Serum stability	+++ 	+
Off-target toxicity (neutrophil)	+ 	+++
Off-target FcγR mediated toxicity	+ 	++
In vivo efficacy (Breast CDX model)*	100 % 	53 %

*Tumor growth inhibition rate (%)

Leveraging AI to accelerate drug development



Incorporating Artificial intelligence / Machine learning into OBI's Discovery and Development Plans



04 Clinical Development

Vice President, Medical
Chen-En Tsai, M.D., Ph.D.



Ongoing Clinical Trials

PRODUCT	TYPE	TARGET	CANCER	DISCOVERY	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3
Adagloxad Simolenin	Vaccine	Globo H	Breast (TNBC)					
OBI-833	Vaccine	Globo H	NSCLC					
OBI-999	ADC (ThioBridge™ conjugation)	Globo H	Multiple Cancers					
OBI-866	Vaccine	SSEA4	Multiple Cancers					
OBI-3424	Prodrug	AKR1C3	Multiple Cancers					



Adagloxad Simolenin (OBI-822)

A First-in-Class Active Immunotherapy
Stimulating Production of Anti-Globo H Antibodies

OBI-822: Globo H covalently linked to keyhole limpet hemocyanin (KLH)



Adagloxad Simolenin Global Phase III Trial



Design

- Randomized, open-label
- Ada Sim + SOC* as study treatment
- SOC as control



Objective

- Primary endpoint: IDFS (invasive disease-free survival)



Population

- Patients with high-risk, early-stage Globo H-positive triple negative breast cancer




Current progress





GLORIA: more than 50% patients enrolled

Target: 668 patients in 2025



*data cut-off: Oct.



GLORIA: First Interim Analysis (Futility Only)



75/187

=

40%


primary
endpoint
events*



Information Fraction



1st Interim analysis



* Primary endpoint event: cancer recurrence or death




Procedure of Interim Futility Analysis:

Based on interim analysis results, **DSMB** will recommend that

- the study proceed as currently designed OR
- the study be discontinued due to futility



Interim analysis time point is reached





OBI-833

A New-Generation Active Immunotherapy Stimulating
Production of Anti-Globo H Antibodies

OBI-833: Globo H covalently linked to **diphtheria toxin**



OBI-833/821 Phase II Study (Non-Small Cell Lung Cancer)




- Design**
- Randomized, open-label
 - OBI-833/821 + EGFR TKI as study treatment
 - EGFR TKI as control



- Objective**
- Primary endpoint: PFS (progression-free survival)



Population



Non-small cell lung cancer

- Patients with Globo H-positive, inoperable, advanced or metastatic NSCLC who have achieved PR or SD after first-line EGFR TKI therapy



Current progress

- EGFR TKI changed from erlotinib to afatinib to align with current clinical practice and enhance enrollment



05 Closing Remarks

Chief Executive Officer
Heidi Wang, Ph.D.



OBI Pharma

Focused Investment in Pipeline of the Future & an Emphasis on Near Term Phase III GLORIA Study

Phase III
GLORIA
Study



2 Distinct ADC
Platforms &
a strong ADC
pipeline



1 Team
Renewal &
Growth



Thank You

※ New drug development requires long process, vast investments and with no guarantee in success which may pose investment risks. The investors are advised to exercise caution and conduct thorough evaluation.

